Arcadia Biosciences
RKDA
13 hedge funds and large institutions have $149K invested in Arcadia Biosciences in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
65% more capital invested
Capital invested by funds: $90.4K → $149K (+$58.6K)
18% more funds holding
Funds holding: 11 → 13 (+2)
1.85% more ownership
Funds ownership: 2.11% → 3.96% (+1.9%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mariner
Overland Park,
Kansas
|
+$71.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$686 |
| 3 |
AssetMark Inc
Concord,
California
|
+$14 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$55 |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$37 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Mariner
Overland Park,
Kansas
| $68.3K | +$71.7K | +25,000 | New |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $39.3K | – | – | – |
|
3
State Street
Boston,
Massachusetts
| $34K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $4.82K | -$55 | -19 | -1% |
|
5
Morgan Stanley
New York
| $1.66K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $652 | +$686 | +239 | New |
|
|
7
Osaic Holdings
Scottsdale,
Arizona
| $205 | -$37 | -13 | -15% |
|
8
Group One Trading
Chicago,
Illinois
| $50 | – | – | – |
|
9
Bank of America
Charlotte,
North Carolina
| $30 | – | – | – |
|
10
US Bancorp
Minneapolis,
Minnesota
| $14 | – | – | – |
|
|
11
AssetMark Inc
Concord,
California
| $14 | +$14 | +5 | New |
|
|
OLVIG
12
Oliver Lagore Vanvalin Investment Group
Flint,
Michigan
| $11 | – | – | – |
|
|
HI
13
Harbour Investments
Madison,
Wisconsin
| $3 | – | – | – |
|
RKDA Hedge Fund Activity: Q3 2024 in Review
13 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q3 2024, worth a combined $149K — up 65% from $90.4K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new RKDA positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Mariner, opening a new position worth an estimated $71.7K. The largest seller was Tower Research Capital (TRC), cutting an estimated $55.
- 13 institutional investors held Arcadia Biosciences (RKDA) as of Q3 2024, up from 11 in Q2 2024.
- Funds reported $149K of Arcadia Biosciences stock for Q3 2024, up 65% quarter-over-quarter.
- 3 funds opened new Arcadia Biosciences positions in Q3 2024 and 1 closed out, a net change of +2 holders.
- The largest Arcadia Biosciences buyer in Q3 2024 was Mariner, an estimated $71.7K added.
- The largest Arcadia Biosciences seller in Q3 2024 was Tower Research Capital (TRC), an estimated $55 sold.
Based on aggregated 13F filings for Q3 2024.